October 23, 2007 - ENDEAVOR IV reached its primary endpoint of target vessel failure non-inferiority when compared to the Taxus stent, according to new 12-month data from Medtronic's ENDEAVOR IV (E-IV) trial presented at TCT 2007.
"It was very gratifying to learn that the Endeavor had similar efficacy compared to Taxus for all lesion subsets," said martin B. Leon, M.D., founder and chariman ermeritus of the Cardiovascular Research Foundation, professor of Medicine, Columbia University medical Center and principal investigator of the ENDEAVOR III and ENDEAVOR IV trials.
The data also said there were no statistically significant difference in TLR or TVR versus Taxus at 12 months. Endeavor also demonstrated superior procedural success, as measured by the trial protocol. Furthermore, no cases of stent thrombosis were reported after six months in the E-IV trial.
For more information: www.medtronic.com